Comparison of Serum SIRT-1 and MMP-9 Levels of Patients With Bronchiectasis and Healthy Controls

NCT ID: NCT06589492

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-02

Study Completion Date

2022-09-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this a cross-sectinol study is to measure the levels of MMP-9 and SIRT-1 levels in patients with bronchiectasis and healthy controls. The aim is to compare the serum levels of these molecules between patients and controls.

* Is the MMP-9 level increasing or decreasing?
* Is the SIRT-1 level increasing or decreasing in patients?
* Is the disease related to age and gender? Participants will only have one 5 ml blood sample drawn when they visit the chest illness clinic. Molecule levels will be measured in this blood's serum.

The patient group participants will be scanned once with high-resolution chest CT.

Apart from this, comparisons will be made using the age and gender information of the participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the overall study population of 60 subjects who applied to the Sivas Cumhuriyet University Faculty of Medicine Research and Practice Hospital Chest Diseases Clinic. The study population was selected regardless of age and gender. Participants selected bronchiectasis patients (n=30) who had symptoms (cough, sputum production) and had their diagnosis confirmed by a chest high-resolution CT scan within the previous year. The study excluded individuals with bronchiectasis not associated with cystic fibrosis and who had a worsening episode (according to the 2017 European Respiratory Society expert consensus criteria) (16) or had taken antibiotics during the previous four weeks. The study enrolled healthy controls (n=30) through advertisements who had acceptable chest X-ray and spirometry results and no lower airway symptoms or serious systemic disorders. The study eliminated individuals who were pregnant or nursing, as well as those with low comprehension. SIRT-1 and MMP-9 levels in the serum of the study group were determined by the ELISA method.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiectasis Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CT scan

Chest high-resolution CT scan will be performed for diagnosis of patients.

Group Type NO_INTERVENTION

No interventions assigned to this group

Age, gender

Age and gender information of patients will be obtained for comparison.

Group Type NO_INTERVENTION

No interventions assigned to this group

Measurement of MMP-9 and SIRT-1 levels in blood serum

It involves taking 5ml of blood from participants to measure mmp-9 and SIRT-1 levels in blood serum.

Group Type EXPERIMENTAL

Measurement of MMP-9 and SIRT-1 levels in blood serum

Intervention Type DIAGNOSTIC_TEST

Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measurement of MMP-9 and SIRT-1 levels in blood serum

Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Bronchiectasis patients who were symptoms (cough, sputum production)
* Individuals whose diagnosis was confirmed by a high-resolution chest CT scan taken within the previous year

Exclusion Criteria

* Individuals with bronchiectasis associated with cystic fibrosis and who had a worsening episode
* individuals who were pregnant or nursing
* those with low comprehension
* taken antibiotics during the previous four weeks
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cumhuriyet University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dilara Ulger Ozbek

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cumhuriyet University

Sivas, Si̇vas Centre, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Biochemistry AD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.